News

A novel transgenic mouse model showing the exacerbating interplay between Abeta- and Tau.P301S-driven pathology
10-06-2016

The interplay of Ab and Tau is still considered detrimental if not crucial for disease etiology and progression of Alzheimer’s Disease.

reMYND to present on Biotechdag
19-10-2015

VIB is organising its 5th Biotechday. All ages are welcome to this free event at campus Gasthuisberg in Leuven. reMYND will be presenting on the research towards the treatment of Alheimers and diabetes worldwide. 

Measuring cognition in reMYND’s Tau animal models
24-06-2015

reMYND’s Tau.P301L and Tau.P301S models feature progressive hyperphosphorylation of Tau with age and a strong correlation of Tau pathology with the motor phenotype.

Longitudinal imaging of Tau aggregates in vivo by two-photon imaging available in reMYND’s Tau.P301S model
06-03-2015

Two-photon imaging allows tracking the formation of Tau aggregates  in the same brain-region of a live animal over the course of time. This makes it possible to study the effects of treatment longitudinally in vivo.

Transgenic mouse model of combined Abeta and tau pathology
17-12-2014

The interplay of Abeta and Tau is considered detrimental if not crucial for disease etiology and progression of Alzheimer’s Disease.

Robust LTP measurements in Tau models
12-11-2014

Long term potentiation (LTP), a reflection of dendritic spine density and synaptic plasticity, is gaining importance as a functional ex-vivo or even in-vivo read-out related to learning and memory.

LTP measurements available through reMYND
11-08-2014

reMYND now offers Long Term Potentiation (LTP) measurements to allow clients to assess the effect of their experimental Alzheimer treatment.

Tau.P301S model available at reMYND’s CRO for efficacy testing of Alzheimer treatments
24-02-2014

Over the last years, more and more tau-treatments are being assessed in mouse models for their potential to treat Alzheimer’s disease. One of the key challenges with many of the tau mouse models is the need for large numbers of animals due to their intrinsic variability.

reMYND’s Tau.P301L mice used to demonstrate efficacy of antibody treatment on behaviour and pathological read-outs
04-11-2013

In the last several years, Tau-directed therapies have gained more interest as a strategy for treating Alzheimer’s Disease.

BMS publishes paper in collaboration with reMYND showing dose-dependent effects of donepezil on brain Abeta and cognition in MWM
08-07-2013

We would like to bring to your attention a recent publication titled “Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer’s disease”.

Pages